COIN). While Wood’s bullish stance on Bitcoin may explain her significant investment in Coinbase, the stock’s impressive rally of nearly 400% in 2023 could also be a contributing factor.\n\nCoinbase’s stock has seen a significant rebound from its all-time lows, currently trading at around $175 per share compared to $32 per share a year ago. This remarkable turnaround is likely driven by more than just a collective “buy-the-dip” mentality. A closer look at the chart reveals that Coinbase’s stock movements closely mirror those of Bitcoin, acting as a proxy for the cryptocurrency market. As crypto prices rise, so does Coinbase’s stock, and vice versa.\n\nOne of the main catalysts for renewed interest in crypto is the possibility of spot Bitcoin ETFs. The Securities and Exchange Commission (SEC) is currently reviewing applications from several companies, including Ark Invest, VanEck, and BlackRock. If approved, these ETFs would provide investors with exposure to Bitcoin without directly purchasing the token itself. BlackRock, the world’s largest money manager, has entered into a strategic partnership with Coinbase, expecting the platform to play a crucial role in the event of spot ETF approval. \n\nInvesting in Coinbase in 2024 is a binary decision. If any of the spot ETFs are approved, we can expect a surge in crypto trading, which would benefit Coinbase. If the SEC does not approve these ETFs, it could lead to a significant sell-off in the crypto market. Investors interested in Coinbase should closely monitor the regulatory environment and its potential impact on the company’s growth.\n\nArk Invest CEO Cathie Wood’s top holding, Coinbase, has seen significant growth in 2023 and could be a potential investment opportunity in 2024.’

'Cingulate incorporated Achieves Major Milestones in Q3 2023\n\nCingulate incorporated, a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology, has announced its financial results for the quarter ended September 30, 2023, along with a clinical and business update. The company's highlights include the presentation of data from its Phase 3 adult efficacy and safety trial, the successful closure of a $4 million public offering, and the conversion of $5.8 million of debt into equity.\n\n"We are pleased with the full data received from the Phase 3 adult efficacy and safety trial, and believe it amplifies our view that the effect size seen with CTx-1301 is positioned to provide substantial benefit to the millions of ADHD patients," said Cingulate Chairman and CEO Shane J. Schaffer.\n\nOn September 11, 2023, Cingulate entered into a Securities Purchase Agreement, resulting in the issuance of 1,720,000 shares of common stock, pre-funded warrants, Series A warrants, and Series B warrants. The offering closed on September 13, 2023, with a combined purchase price per share of common stock and accompanying warrants at $0.5776, and a combined purchase price per pre-funded warrant and accompanying warrants at $0.5775. The Series A and Series B warrants have an exercise price of $0.5776 per share and will expire on November 3, 2028 and November 3, 2025, respectively. The issuance of common stock upon the exercise of the warrants was approved by the Company's stockholders at a special meeting held on November 3, 2023. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.\n\nIn addition, on September 8, 2023, Werth Family Investment Associates, LLC ("WFIA"), the manager of which is Peter J. Werth, a member of the Cingulate board of directors, converted $5.8 million of debt and accrued interest into pre-funded warrants to purchase 6,838,235 shares of Cingulate common stock. The pre-funded warrants have no expiration date and are exercisable immediately at an exercise price of $0.0001 per share, subject to a beneficial ownership blocker of 19.99%.\n\nCingulate also presented full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit hyperactivity disorder (ADHD), at the 36th Annual Psych Congress in Nashville, TN on September 8, 2023. The study, which was not powered for statistical significance, demonstrated a strong effect size of CTx-1301 in 21 adults with ADHD.\n\n'